Mark - Asabys Partners

Portfolio

October 17, 2023

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

READ THIS NEWS IN SPANISH SpliceBio is eligible to receive upfront, opt-in and milestone payments…

Mark

Portfolio

October 11, 2023

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

READ THIS NEWS IN SPANISH Round led by Fidelity Management & Research Company with participation…

Mark

Portfolio

October 11, 2023

Sidekick Health announces landmark acquisition, expanding its portfolio to offer regulated Prescription Digital Therapeutics

READ THIS NEWS IN SPANISH The acquisition of aidhere strengthens Sidekick Health’s digital health offering…

Mark

Portfolio

October 5, 2023

Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial

FDA Fast Track designation received for AGMB-129 in Fibrostenosing Crohn’s Disease. Global 12-week Phase 2a…

Mark

Portfolio

September 20, 2023

INBRAIN Neuroelectronics announces FDA Breakthrough Device designation for its graphene-based intelligent network modulation platform

A first-of-a-kind device, the INBRAIN Intelligent Network Modulation System is designed to offer a new…

Mark

Portfolio

September 14, 2023

El ICF invierte 10M€ en el fondo II de Asabys, que ya cuenta con 3 empresas participadas

READ THIS NEWS IN CATALAN READ THIS NEWS IN ENGLISH Sabadell Asabys II anunció el…

Mark

Portfolio

September 7, 2023

Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys

READ THIS NEWS IN SPANISH Thuja Capital and founding investor Sofinnova Partners also joined the…

Mark

Portfolio

July 18, 2023

Orikine Bio closes €5.5m Series Seed Financing with Sabadell Asabys and AdBio

READ THIS NEWS IN SPANISH New synthetic biology spin-off from the Centre for Genomic Regulation…

Mark

Portfolio

June 21, 2023

Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys

READ THIS NEWS IN SPANISH The technology developed by Nuage Therapeutics allows targeting intrinsically disordered…

Mark

Portfolio

May 23, 2023

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development ONA Therapeutics…

Mark

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others